CASI Pharmaceuticals Gets a Buy Rating from Maxim Group

By Jason Carr

Maxim Group analyst Gabrielle Zhou reiterated a Buy rating on CASI Pharmaceuticals (NASDAQ: CASI) today and set a price target of $4. The company’s shares closed yesterday at $1.03.

Zhou commented:

“CASI Pharmaceuticals reported 1Q17 results with a net loss of $1.7M or ($0.03) per share. The company ended the period with $25.5M of cash on the balance sheet.”

According to TipRanks.com, Zhou is ranked 0 out of 5 stars with an average return of -11.6% and a 24.5% success rate. Zhou covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Sciclone Pharmaceuticals.

CASI Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $4.

The company has a one year high of $1.76 and a one year low of $0.82. Currently, CASI Pharmaceuticals has an average volume of 42.49K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. The drugs are Captisol-Enabled, ZEVALIN and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.